Academic spin-out PEP-Therapy S.A.S. can now start a first-in-human clinical trial evaluating its lead asset PEP-010 as a potential tumor killer following a series A financing that raised €5.4m ($6.4m) in two successful stages, the biotech’s CEO told Scrip.
PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy’s proprietary Cell Penetrating & Interfering Peptide...